Correction: Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis

Frontiers in Immunology 2026 Open access

Read full text
Authors: Wenjing Hao, Jun Zhang, Yunxia Wang, Boyu Fang, Shasha Jin, Jing Yuan, Weimin Cai
DOI: 10.3389/fimmu.2026.1812769
Cited by: 0

Abstract

Corrigendum on: Hao W, et al. (2023) Immune-related adverse events associated with nabpaclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis. Front. Immunol. 14:1175809. doi: 10.3389/fimmu.2023.1175809In the published article, there was an error in the Funding statement. [This work was supported by grant from the National Natural Science Foundation of China [Grant No. 8217130423]].The correct Funding statement appears below.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Cancer Treatment and Pharmacology Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1812769–1812769
Publication date
5 March 2026
Language
EN